Alzamend Neuro (ALZN) Competitors $1.10 +0.10 (+10.00%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.06 -0.04 (-3.18%) As of 03/27/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. CARA, GRCE, CLDI, ALLK, FNCH, JATT, CVM, CYTH, LIAN, and CMMBShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Cara Therapeutics (CARA), Grace Therapeutics (GRCE), Calidi Biotherapeutics (CLDI), Allakos (ALLK), Finch Therapeutics Group (FNCH), JATT Acquisition (JATT), CEL-SCI (CVM), Cyclo Therapeutics (CYTH), LianBio (LIAN), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Cara Therapeutics Grace Therapeutics Calidi Biotherapeutics Allakos Finch Therapeutics Group JATT Acquisition CEL-SCI Cyclo Therapeutics LianBio Chemomab Therapeutics Cara Therapeutics (NASDAQ:CARA) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Do analysts rate CARA or ALZN? Cara Therapeutics presently has a consensus target price of $27.84, suggesting a potential upside of 417.47%. Alzamend Neuro has a consensus target price of $20.00, suggesting a potential upside of 1,718.18%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Cara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, CARA or ALZN? Alzamend Neuro has lower revenue, but higher earnings than Cara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$7.14M3.45-$118.51M-$21.01-0.26Alzamend NeuroN/AN/A-$9.95MN/AN/A Do insiders & institutionals have more ownership in CARA or ALZN? 44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CARA or ALZN? In the previous week, Alzamend Neuro had 5 more articles in the media than Cara Therapeutics. MarketBeat recorded 6 mentions for Alzamend Neuro and 1 mentions for Cara Therapeutics. Cara Therapeutics' average media sentiment score of 1.87 beat Alzamend Neuro's score of 0.70 indicating that Cara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cara Therapeutics Very Positive Alzamend Neuro Positive Which has more risk and volatility, CARA or ALZN? Cara Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Is CARA or ALZN more profitable? Alzamend Neuro has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Alzamend Neuro's return on equity of 0.00% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% Alzamend Neuro N/A N/A -289.14% Does the MarketBeat Community believe in CARA or ALZN? Cara Therapeutics received 660 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 100.00% of users gave Alzamend Neuro an outperform vote while only 72.42% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66772.42% Underperform Votes25427.58% Alzamend NeuroOutperform Votes7100.00% Underperform VotesNo Votes SummaryAlzamend Neuro beats Cara Therapeutics on 10 of the 15 factors compared between the two stocks. Remove Ads Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.26M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E RatioN/A7.2024.5919.03Price / SalesN/A225.82383.9393.17Price / CashN/A65.6738.1634.64Price / Book-0.316.476.944.33Net Income-$9.95M$141.90M$3.20B$247.06M7 Day Performance12.44%-3.02%-2.30%-0.53%1 Month Performance31.34%-4.63%3.07%-3.74%1 Year Performance-89.22%-8.61%11.15%1.72% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro3.5164 of 5 stars$1.10+10.0%$20.00+1,718.2%-89.2%$7.26MN/A0.004Short Interest ↓Gap UpCARACara Therapeutics4.0035 of 5 stars$5.12-0.2%$27.84+443.8%-48.4%$23.42M$7.14M-0.2480Positive NewsGRCEGrace Therapeutics2.4709 of 5 stars$2.29+5.0%$12.00+424.0%N/A$23.22MN/A-1.97N/APositive NewsCLDICalidi Biotherapeutics2.1506 of 5 stars$0.87+2.2%$16.67+1,817.9%N/A$23.00M$50,000.000.0038News CoverageALLKAllakos4.6399 of 5 stars$0.25+2.8%$2.00+687.7%-81.7%$22.68MN/A-0.13190Short Interest ↓Positive NewsFNCHFinch Therapeutics GroupN/A$13.75+0.7%N/A+403.5%$22.08M$110,000.00-1.56190JATTJATT AcquisitionN/A$1.28+18.5%N/A-35.8%$22.08MN/A0.003High Trading VolumeCVMCEL-SCIN/A$0.28-6.5%N/A-87.4%$21.94MN/A-0.5943Gap UpHigh Trading VolumeCYTHCyclo Therapeutics2.8933 of 5 stars$0.66-5.6%$0.95+43.7%N/A$21.76M$870,725.00-0.739Upcoming EarningsShort Interest ↓LIANLianBioN/A$0.20flatN/A-38.0%$21.61MN/A-0.25110Gap DownCMMBChemomab Therapeutics3.6877 of 5 stars$1.50+6.4%$9.00+500.0%+42.9%$21.54MN/A-1.5020Short Interest ↓News CoverageGap Up Remove Ads Related Companies and Tools Related Companies Cara Therapeutics Competitors Grace Therapeutics Competitors Calidi Biotherapeutics Competitors Allakos Competitors Finch Therapeutics Group Competitors JATT Acquisition Competitors CEL-SCI Competitors Cyclo Therapeutics Competitors LianBio Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALZN Stock Free ALZN Stock Alerts